COMMUNIQUÉS West-GlobeNewswire

Dogwood Therapeutics Appoints Iain Dukes, Venture Partner at OrbiMed, as Chair of Scientific Advisory Board
30/06/2026
Veteran Biopharma Executive and Venture Investor to Lead Newly Formed Dogwood Advisory Board in advance of Halneuron® Phase 2b Data Which is Projected for Fall of 2026 ALPHARETTA, Ga., June 30, 2026 (GLOBE NEWSWIRE) -- [...]
Adam Ferrari Health Science Scholarship Closes 2026 Application Window
30/06/2026
The Ferrari Foundation Begins Finalist Review for Its $20,000 Award, with a Recipient to Be Named September 1, 2026 IRVINE, Calif., June 30, 2026 (GLOBE NEWSWIRE) -- The Ferrari Foundation has closed the 2026 [...]
Psychemedics Releases 2026 Education Insights Report
30/06/2026
New Report Examines Emerging Student Substance Use Trends and Their Impact on Academic Success, Student Wellness, and Campus Safety DALLAS, June 30, 2026 (GLOBE NEWSWIRE) -- Psychemedics Corporation, the pioneer and [...]
FDA Selects Kyowa Kirin for PreCheck Pilot Program to Accelerate Manufacturing Timelines and Enhance Supply Chain Resilience
30/06/2026
Strategic collaboration at Sanford, North Carolina facility, currently under construction, to optimize cGMP validation, accelerate time-to-market for complex biologics, and shore up U.S. medicine supply TOKYO and [...]
ReFocus Eye Health Partners with Solinsky EyeCare, Expanding its Comprehensive Eye Care Network
30/06/2026
New affiliation unites one of Connecticut’s most trusted ophthalmology practices with ReFocus’ growing, physician-led network, expanding access to exceptional eye care across 11 locations throughout the greater Hartford [...]
Quince Therapeutics Appoints Recognized Leaders in Pulmonary Medicine to Scientific Advisory Board
30/06/2026
SOUTH SAN FRANCISCO, Calif., June 30, 2026 (GLOBE NEWSWIRE) -- Quince Therapeutics, Inc. (Nasdaq: QNCX), a clinical stage biopharmaceutical company focused on the development of novel, disease modifying therapies for [...]
Flare Therapeutics Secures $85M in Insider-Led Series C Financing and Appoints Anna Protopapas as Chief Executive Officer
30/06/2026
- Proceeds will fund advancement of AR ON degrader, FX-111, to proof of concept and preclinical development of AR ON RIPTAC program - Veteran biotech executive, Anna Protopapas, appointed as CEO to guide company through [...]
U.S. Renal Care and Akebia Announce Interim Analysis of VOICE Trial Demonstrated Overwhelming Statistical Evidence of Improved Safety Outcomes for Patients Treated with Vafseo versus an ESA
30/06/2026
Vafseo ® demonstrated a clinically meaningful safety outcome benefit in U.S. patients with anemia due to CKD on dialysis utilizing TIW dosing regimen Primary Investigator to stop trial on recommendation from Independent [...]
Cogent Biosciences Announces Submission of New Drug Application (NDA) for Bezuclastinib in Advanced Systemic Mastocytosis (AdvSM)
30/06/2026
Submission based on results of APEX pivotal trial which demonstrated bezuclastinib objective response rate (CR+CRh+PR+CI) of 65% per mIWG criteria and 81% ORR per PPR criteria with a well-tolerated safety profile for [...]
MediciNova CEO Provides Shareholder Update
30/06/2026
LA JOLLA, Calif., June 30, 2026 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ: MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875 [...]
Candel Therapeutics Announces Initiation of Global Pivotal Phase 3 AURORA Trial Evaluating Aglatimagene Besadenovec (CAN-2409) in Advanced Non-Small Cell Lung Cancer Patients with Inadequate Response to Immune Checkpoint Inhibitors
30/06/2026
Phase 3 clinical trial will evaluate aglatimagene besadenovec plus valacyclovir in combination with continued pembrolizumab versus standard-of-care docetaxel chemotherapy in patients with metastatic, non-squamous, non- [...]
Provectus Biopharmaceuticals and VisiRose Announce U.S. Patent Award for Light-Independent Antibacterial Eye Drop Targeting Drug-Resistant Ocular Infections
30/06/2026
New IP covers topical rose bengal sodium ophthalmic composition against MRSA and other resistant Gram-positive bacteria without requiring light activation. VisiRose to hold exclusive ophthalmic license. KNOXVILLE, Tenn [...]
Allarity Therapeutics Announces the Grant of Essential U.S. Patent for Its Stenoparib DRP® Companion Diagnostic
30/06/2026
Key U.S. patent now protects exclusivity for developing stenoparib with the stenoparib-DRP ® until April 2042 TARPON SPRINGS, Fla., June 30, 2026 – Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR [...]
FEATOL Rolls Out Reinforced Lower Back Brace to Help Adults During Work, Driving, and in Chronic Pain
30/06/2026
The latest adjustable lumbar support from FEATOL combines stability with comfort, providing much-needed mobility support for those experiencing lower back fatigue NEW YORK, June 30, 2026 (GLOBE NEWSWIRE) -- With more [...]
Monopar Therapeutics Receives FDA Rare Pediatric Disease Designation for ALXN1840 for the Treatment of Wilson Disease
30/06/2026
WILMETTE, Ill., June 30, 2026 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (“Monopar” or the “Company”) (Nasdaq: MNPR), a clinical-stage biopharmaceutical company developing innovative treatments for patients with [...]
Weight Watchers Med+ Establishes Access to GLP-1s Through Medicare GLP-1 Bridge Program
30/06/2026
Weight Watchers expands access for Med+ Medicare beneficiaries to GLP-1 medications covered by the Medicare Bridge Program. NEW YORK, June 30, 2026 (GLOBE NEWSWIRE) -- WW International, Inc. (NASDAQ: WW) (“Weight [...]
SCYNEXIS Initiates Phase 1 Study of SCY-770, a Novel AMPK Activator for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)
30/06/2026
Dose-optimization data from the Phase 1 study expected Q3 2026 to support Phase 2 proof-of-concept initiation in ADPKD in Q4 2026 JERSEY CITY, N.J., June 30, 2026 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX ), a [...]
Genelux Announces Publication of Translational Analysis Supporting Immune Activation and Chemotherapy Sensitization with Olvi‑Vec in Ovarian Cancer
30/06/2026
- Findings provide mechanistic support for previously reported clinical outcomes of clinical reversal of platinum resistance/refractoriness from Phase 2 VIRO-15 trial - - Data demonstrate Olvi-Vec–mediated modulation of [...]
Biodexa Announces Pricing of $3.5 Million Registered Direct Offering & Concurrent Private Placement of Pre-Funded Warrants and Warrants
30/06/2026
June 30, 2026 Biodexa Announces Pricing of $3.5 Million Registered Direct Offering & Concurrent Private Placement of Pre-Funded Warrants and Warrants Biodexa Pharmaceuticals PLC, (Nasdaq: BDRX) (“Biodexa” or the “ [...]

Pages